Correspondence

Government response to the ACMD on CBPMs in humans

The government responds to the ACMD reports on cannabis-based products for medicinal use (CBPMs) in humans.

• From: Advisory Council on the Misuse of Drugs
• Published: 21 January 2022

Documents

Government response letter to the ACMD on CBPMs in humans (accessible version)

HTML

Government response letter to the ACMD on CBPMs in humans

PDF, 82.1 KB, 3 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The letter responds to:

• the ACMD letter to the government dated 23 December 2019 about the outline assessment framework setting out how the ACMD would assess the various impacts of the rescheduling, and the data sources that would be used
• the 27 November 2020 report on CBPMs in humans, which considered the impact of rescheduling CBPMs under the Misuse of Drugs Regulations 2001 and separate advice on whether the current scheduling of CBPMs remained appropriate

Published 21 January 2022